The Interaction of the Von Willebrand Factor-A1 Domain with Platelet Glycoprotein Ib/IX. The Role of Glycosylation and Disulfide Bonding in a Monomeric Recombinant A1 Domain Protein
Overview
Authors
Affiliations
The interaction of von Willebrand factor (vWF) with platelet glycoprotein Ib/IX plays an important role in primary hemostasis. Previous studies have localized the GpIb alpha binding domain of vWF to amino acid residues 449-728, a region containing the vWF-A1 domain. In order to assess the role of A1 domain structure in vWF binding functions, a cDNA encoding residues 475-709 of vWF was expressed in Escherichia coli (non-glycosylated) and in Chinese hamster ovary (CHO) cells (glycosylated). These recombinant proteins contain a single intrachain disulfide bond between C509 and C695 and were purified as monomers with apparent molecular weights of 36,000 (E. coli) and 39,000 (CHO). 35S-Labeled-vWF-A1 proteins bound directly to GpIb/IX receptors on platelets. The non-glycosylated form had a slightly higher affinity (Kd = 1.4 +/- 0.4 microM) than the glycosylated vWF-A1 protein (Kd = 4.5 +/- 0.9 microM) but had similar binding capacity of 28,000 GpIb/IX-specific binding sites per platelet. Additionally, both recombinant vWF-A1 proteins bound to heparin but neither bound to immobilized type I and III collagen. Both E. coli- and CHO-derived vWF-A1 proteins inhibited ristocetin-induced platelet agglutination with IC50 values of 300 and 700 nM, respectively. Reduction of the only disulfide bond between C509 and C695 abolished platelet binding activity at concentration up to 2 microM of protein. Confirmation of the importance of the 509-695 disulfide bond was obtained from a full-length vWF mutant containing substitutions at C509 and C695 (C509/695S) which failed to bind to the platelet GpIb/IX receptor. These studies document that vWF-A1 domain can bind to GpIb/IX and heparin but not collagen, and that binding to GpIb/IX requires an intact disulfide bond between C509 and C695. Furthermore, glycosylation increases the solubility but reduces binding affinity of recombinant vWF A1.
Liang Q, Parker E, Dean G, Karpen M, Wu Y, Wang X J Thromb Haemost. 2024; 22(7):2052-2058.
PMID: 38704122 PMC: 11214880. DOI: 10.1016/j.jtha.2024.04.015.
Lentiviral gene therapy reverts GPIX expression and phenotype in Bernard-Soulier syndrome type C.
Martinez-Navajas G, Ceron-Hernandez J, Simon I, Lupianez P, Diaz-McLynn S, Perales S Mol Ther Nucleic Acids. 2023; 33:75-92.
PMID: 37416759 PMC: 10320622. DOI: 10.1016/j.omtn.2023.06.008.
Type 2B von Willebrand disease mutations differentially perturb autoinhibition of the A1 domain.
Legan E, Liu Y, Arce N, Parker E, Lollar P, Zhang X Blood. 2022; 141(10):1221-1232.
PMID: 36580664 PMC: 10023833. DOI: 10.1182/blood.2022017239.
Zhao Y, Wang H, Wang Y, Lou J, Ju L RSC Chem Biol. 2022; 3(6):707-720.
PMID: 35755187 PMC: 9175105. DOI: 10.1039/d2cb00010e.
Hidden Relationships between -Glycosylation and Disulfide Bonds in Individual Proteins.
Bakshi T, Pham D, Kaur R, Sun B Int J Mol Sci. 2022; 23(7).
PMID: 35409101 PMC: 8998389. DOI: 10.3390/ijms23073742.